In hematological cancers, it was demonstrated that bone marrow-derived MSCs-Exo delivers miRNA-222-3p to THP-1 cells (leukemia cell), which target the IRF2 gene, consequently down-regulate the IRF2/INPP4B signaling, resulting in the inhibition of cell proliferation and the leukemia progression as well as the induction of apoptosis [73]. This evidence concerns the gene IRF2 and hematopoietic and lymphoid cell neoplasm.